

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Geyer 1



Continu 1				
Section 1. Identifying Inform	nation			
1. Given Name (First Name) Mark	2. Surname (Last Na Geyer	me) 3. Date 16-March-2019		
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Renier J. Brentjens		
5. Manuscript Title Safety and tolerability of conditioning of	chemotherapy follow	ved by CD19-targeted CAR T-cells for relapsed/refractory C	LL	
6. Manuscript Identifying Number (if you kr 122627-INS-CMED-RV-2	now it)			
Section 2. The Work Under Co	oncidovation for F	nahlisation		
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not limited to graest? Yes ormation below. If yo	s from a third party (government, commercial, private foundatior nts, data monitoring board, study design, manuscript preparation No bu have more than one entity press the "ADD" button to ad	n,	
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Other? Comments		
uno Therapeutics		Financial support to institution for the clinical trial described within the manuscript.		
ymphoma Research Foundation	✓			
merican Society of Hematology	✓			
NIH/National Center for Advancing Translational Sciences				
Section 3. Relevant financial	activities outside	the submitted work.		
of compensation) with entities as descr	ibed in the instruction port relationships the ———————————————————————————————————	te whether you have financial relationships (regardless of a ons. Use one line for each entity; add as many lines as you n at were present during the 36 months prior to publicati No	need by	
If yes, please fill out the appropriate information below.				

Geyer 2



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments		
Dava Oncology		✓			Honorarium for giving educational talk for which I controlled all content.		
Section 4. Intellectual Property Patents & Copyrights							
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes V No		
Section 5. Relationships not c	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/cond	itions/cir	cumstance	es are present (exp	olain belo	w):		
✓ No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Stateme	nt						
Based on the above disclosures, this form below.		omatically (generate a disclos	sure state	ment, which will appear in the box		
Dr. Geyer reports other from Juno Thera Society of Hematology, grants from NIH, study; personal fees from Dava Oncolog	/National	Center for	Advancing Trans				

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Geyer 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Information	ation					
1. Given Name (First Name) Isabelle	2. Surname (Last Rivière	Name)		3. Date 16-March-2019		
4. Are you the corresponding author?	Yes ✓ N	·	Corresponding Author's Name Renier J. Brentjens			
5. Manuscript Title Safety and tolerability of conditioning ch	nemotherapy fol	lowed by CD19-targ	eted CAR	T-cells for relapsed/refractory CLL		
6. Manuscript Identifying Number (if you kno 122627-INS-CMED-RV-2	ow it)					
Section 2. The Work Under Co	nsideration fo	r Publication				
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)?						
Are there any relevant conflicts of interes	st? ✓ Yes	No				
If yes, please fill out the appropriate info		f you have more than	n one enti	ty press the "ADD" button to add a row.		
Excess rows can be removed by pressing						
Name of Institution/Company	Grant? Perso	2	Other?	Comments		
Juno Therapeutics			✓	Financial support to institution for the clinical trial described within the manuscript.		
NIH/National Cancer Institute (P30-CA08748)	✓					
Section 3. Relevant financial a	ctivities outsi	de the submitted	work.			
Place a check in the appropriate boxes ir of compensation) with entities as described clicking the "Add +" box. You should rep	oed in the instru	ctions. Use one line f	or each er	ntity; add as many lines as you need by		
Are there any relevant conflicts of interes		No				
If yes, please fill out the appropriate info	rmation below.					
Name of Entity	Grant? Perso	2 2	Other?	Comments		
Fate Therapeutics			V	Consulting fee; contracted research;		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
FloDesign Sonics				✓	Contracted research; ownership interest	
Juno Therapeutics		√		✓	Contracted research; consulting/ advisory role; royalty sharing agreement; stock ownership	
Takeda				✓	Contracted research	
Atara				✓	Contracted research	
Section 4. Intellectual Propert	v Pate	ents & Coi	ovrights			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo						
Section 5. Relationships not covered above						
Are there other relationships or activities potentially influencing, what you wrote in				nfluence	d, or that give the appearance of	
Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, joi On occasion, journals may ask authors to						
Section 6. Disclosure Statemen	nt					
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ment, which will appear in the box	
Dr. Rivière reports other from Juno Therapeutics, grants from NIH/National Cancer Institute (P30-CA08748), during the conduct of the study; other from Fate Therapeutics, other from FloDesign Sonics, other from Juno Therapeutics, other from Takeda, other from Atara, outside the submitted work; .						



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent

Sénéchal 1



Section 1. Identifying	ng Information		
1. Given Name (First Name) Brigitte	2. Surname (Last Sénéchal	lame)	3. Date 16-March-2019
4. Are you the corresponding at	ıthor? Yes ✓ N	Corresponding Autho	or's Name
5. Manuscript Title Safety and tolerability of con	ditioning chemotherapy foll	wed by CD19-targeted CAR	T-cells for relapsed/refractory CLL
6. Manuscript Identifying Numb	er (if you know it)		
Section 2. The Work	Under Consideration fo	Publication	
			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Are there any relevant conflic	ts of interest? Yes	No	
If yes, please fill out the appro Excess rows can be removed		ou have more than one enti	ty press the "ADD" button to add a row.
Name of Institution/Compa	Porco	Non-Financial Other?	Comments
luno Therapeutics			Financial support to institution (not to this individual) for the clinical trial described within the manuscript.
Section 3. Relevant	financial activities outsion	e the submitted work.	
of compensation) with entitie	es as described in the instruc	ions. Use one line for each er	cial relationships (regardless of amount ntity; add as many lines as you need by a 36 months prior to publication .
Are there any relevant conflic	ts of interest? Yes	No	
Section 4. Intellectu			
Intellectu	al Property Patents & (<u>opyrights</u>	
Do you have any patents, wh	ether planned, pending or is	ued, broadly relevant to the	work? ☐ Yes ✓ No

Sénéchal 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Sénéchal reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Sénéchal 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Info	rmation	
1. Given Name (First Name) Xiuyan	2. Surname (Last Name) Wang	3. Date 16-March-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Renier J. Brentjens
5. Manuscript Title Safety and tolerability of conditionin	g chemotherapy followed by	CD19-targeted CAR T-cells for relapsed/refractory CLL
6. Manuscript Identifying Number (if you 122627-INS-CMED-RV-2	know it)	
Section 2. The Work Under	Consideration for Public	ation
		a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of int		
If yes, please fill out the appropriate i Excess rows can be removed by press		re more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Nor	n-Financial Other? Comments
luno Therapeutics		Financial support to institution (not to this individual) for the clinical trial described within the manuscript.
Section 3. Relevant financi	al activities outside the s	ubmitted work.
of compensation) with entities as des	scribed in the instructions. Us	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication .
Are there any relevant conflicts of int	erest?	
Section 4. Intellectual Prop	erty Patents & Copyric	ghts
Do you have any patents, whether pl	anned, pending or issued, br	oadly relevant to the work? Yes V No



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Wang reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	nation				
1. Given Name (Fi Yongzeng	rst Name)	2. Surname (Last Na Wang	me) 3. Date 16-March-2019			
4. Are you the cor	responding author?	Yes No Corresponding Author's Name Renier J. Brentjens				
5. Manuscript Title Safety and tolera		hemotherapy follov	ved by CD19-targeted CAR T-cells for relapsed/refractory CLL			
6. Manuscript lder 122627-INS-CME	ntifying Number (if you kr :D-RV-2	now it)				
Section 2.						
Did you or your ins any aspect of the s statistical analysis, Are there any rele	ubmitted work (including etc.)? evant conflicts of intere	ive payment or service but not limited to gra	s from a third party (government, commercial, private foundation, etc.) for nts, data monitoring board, study design, manuscript preparation, No			
	but the appropriate info be removed by pressin	-	ou have more than one entity press the "ADD" button to add a row.			
Name of Institut	ion/Company	Grant? Persona Fees?	Non-Financial Other? Comments			
luno Therapeutics			Financial support to institution (not to this individual) for the clinical trial described within the manuscript.			
	ı					
Section 3.	Relevant financial	activities outside	the submitted work.			
of compensation clicking the "Add) with entities as descri +" box. You should rep	bed in the instruction ort relationships th	te whether you have financial relationships (regardless of amount ons. Use one line for each entity; add as many lines as you need by at were present during the 36 months prior to publication .			
Are there any rel	evant conflicts of intere	est? Yes ✓	No			
Section 4.	Intellectual Proper	ty Patents & Co	ppyrights			
Do you have any	patents, whether plan	ned, pending or issu	ed, broadly relevant to the work? Yes V No			



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Wang reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Purdon 1



Section 1.	Identifying Inform	ation			
1. Given Name (Fire Terence		2. Surname (Last N	lame)		Date -March-2019
4. Are you the corre	esponding author?	☐ Yes ✓ No	Correspon Renier J. E	ding Author's Name Brentjens	
5. Manuscript Title Safety and toleral	oility of conditioning c	hemotherapy follo	wed by CD19-targe	eted CAR T-cells for	relapsed/refractory CLL
6. Manuscript Iden 122627-INS-CMEI	tifying Number (if you kn D-RV-2	ow it)			
Section 2.	The Work Under Co	onsideration for	Publication		
, ,	bmitted work (including			_	ercial, private foundation, etc.) for n, manuscript preparation,
	vant conflicts of intere	est? ✓ Yes	No		
	ut the appropriate info e removed by pressing		you have more thar	n one entity press tl	he "ADD" button to add a row.
Name of Instituti		Grant? Person	al Non-Financial	Other? Comme	ents
luno Therapeutics				✓ to this ind	support to institution (not lividual) for the clinical trial within the manuscript.
Section 3.	Relevant financial	activities outsid	e the submitted	work.	
of compensation)	with entities as descri	bed in the instruct	ions. Use one line f	or each entity; add	nships (regardless of amount as many lines as you need by ths prior to publication.
Are there any rele	vant conflicts of intere	est? Yes	No		
Section 4.	Intellectual Proper	ty Patents & C	opyrights		
Do you have any	oatents, whether plani	ned, pending or iss	sued, broadly releva	ant to the work?	Yes ✓ No

Purdon 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Purdon reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Purdon 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Hsu 1



Section 1.	Identifying Inform	nation			
1. Given Name (Fi Meier		2. Surname (Last I Hsu	Name)		Date -March-2019
4. Are you the corresponding author?		Yes ✓ No Corresponding Author's Name Renier J. Brentjens			
5. Manuscript Title Safety and tolera		hemotherapy follo	owed by CD19-targ	eted CAR T-cells for	relapsed/refractory CLL
6. Manuscript Idei 122627-INS-CME	ntifying Number (if you kr ED-RV-2	now it)			
	ı				
Section 2.	The Work Under Co	onsideration for	Publication		
	ubmitted work (including				ercial, private foundation, etc.) for , manuscript preparation,
=	evant conflicts of intere	est? ✓ Yes	No		
	out the appropriate info be removed by pressing		you have more tha	n one entity press tl	ne "ADD" button to add a row.
Name of Institut		Grant? Person	al Non-Financial	Other? Comme	ents
luno Therapeutics				✓ to this ind	support to institution (not ividual) for the clinical trial within the manuscript.
Section 3.	Relevant financial	activities outsid	e the submitted	work.	
of compensation	n) with entities as descri	bed in the instruct	ions. Use one line f	or each entity; add	nships (regardless of amount as many lines as you need by the prior to publication.
Are there any rel	evant conflicts of intere	est? Yes	/ No		
	ı				
Section 4.	Intellectual Proper	ty Patents & C	Copyrights		
Do you have any	patents, whether plan	ned, pending or is:	sued, broadly relev	ant to the work?	Yes ✓ No

Hsu 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Hsu reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Hsu 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

1

Devlin



Section 1. Identifying Inform	nation				
1. Given Name (First Name) Sean	2. Surname (Last Name) Devlin		3. Date 16-March-2019		
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author	or's Name		
5. Manuscript Title Safety and tolerability of conditioning of	:hemotherapy followed by	CD19-targeted CAR	T-cells for relapsed/refractory CLL		
6. Manuscript Identifying Number (if you kr 122627-INS-CMED-RV-2	now it)				
Section 2. The Work Under Co	onsideration for Public	cation			
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)?			ent, commercial, private foundation, etc.) for udy design, manuscript preparation,		
Are there any relevant conflicts of interes					
If yes, please fill out the appropriate info Excess rows can be removed by pressin	•	e more than one enti	ity press the "ADD" button to add a row.		
Name of Institution/Company	Grant'	n-Financial Other?	Comments		
luno Therapeutics			Financial support to institution (not to this individual) for the clinical trial described within the manuscript.		
Section 3. Relevant financial	activities outside the s	submitted work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication .					
Are there any relevant conflicts of interes		e present during th	e 30 months prior to publication.		
Section 4. Intellectual Proper	rty Patents & Copyric	yhts			
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the	work? ☐ Yes ✓ No		

Devlin 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Devlin reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Devlin 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Palomba 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fii M. Lia		2. Surname (Last Name) Palomba			3. Date 16-March-2019		
4. Are you the cor	responding author?	Yes ✓	No	Corresponding Author's Name Renier J. Brentjens			
5. Manuscript Title Safety and tolera		hemotherapy f	ollowed by	CD19-targe	eted CAR	T-cells for relapsed/refractory CLL	
6. Manuscript Ider 122627-INS-CME	ntifying Number (if you kr ED-RV-2	ow it)					
Section 2							
Section 2.	The Work Under Co	onsideration [•]	for Public	ation			
any aspect of the s statistical analysis,	ubmitted work (including	but not limited t				ent, commercial, private foundation, etc.) for udy design, manuscript preparation,	
If yes, please fill o	out the appropriate info	ormation below		e more than	one enti	ity press the "ADD" button to add a row.	
excess rows carri	be removed by pressing						
Name of Institut	ion/Company	Grant		-Financial upport	Other?	Comments	
luno Therapeutics					✓	Financial support to institution for the clinical trial described within the manuscript.	
Section 3.	Relevant financial	activities out	side the s	ubmitted	work.		
of compensation) with entities as descri	bed in the instr	uctions. Use	e one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by a 36 months prior to publication .	
Are there any rele	evant conflicts of intere	est? Yes	✓ No				
	l						
Section 4.	Intellectual Proper	ty Patents a	& Copyrig	hts			
Do you have any	patents, whether plan	ned, pending o	r issued, bro	oadly releva	nt to the	work? ☐ Yes ✓ No	

Palomba 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Palomba reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Palomba 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Lizanza de The material has been licensed to an

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Halton 1



Section 1.	Identifying Inform	ation	
1. Given Name (Fi Elizabeth	rst Name)	2. Surname (Last Na Halton	ame) 3. Date 16-March-2019
4. Are you the corresponding author?		Yes ✓ No	Corresponding Author's Name Renier J. Brentjens
5. Manuscript Title Safety and tolera		hemotherapy follow	ved by CD19-targeted CAR T-cells for relapsed/refractory CLL
6. Manuscript Ider 122627-INS-CME	ntifying Number (if you kr ED-RV-2	now it)	
Section 2.			
Did you or your ins any aspect of the s statistical analysis, Are there any rel	ubmitted work (including etc.)? evant conflicts of intere	ive payment or service but not limited to gra	es from a third party (government, commercial, private foundation, etc.) for ants, data monitoring board, study design, manuscript preparation,
	but the appropriate into be removed by pressin	-	ou have more than one entity press the "ADD" button to add a row.
Name of Institut	ion/Company	Grant? Persona Fees?	Non-Financial Support? Comments
luno Therapeutics			Financial support to institution (not to this individual) for the clinical trial described within the manuscript.
Section 3.	Relevant financial	activities outside	the submitted work.
of compensation clicking the "Add) with entities as descri +" box. You should rep	bed in the instruction ort relationships th	onte whether you have financial relationships (regardless of amount ons. Use one line for each entity; add as many lines as you need by at were present during the 36 months prior to publication .
Are there any rel	evant conflicts of intere	est?	No
Section 4.	Intellectual Proper	ty Patents & Co	ppyrights
Do you have any	patents, whether plan	ned, pending or issu	ued, broadly relevant to the work? ☐ Yes ✓ No

Halton 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Halton reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Halton 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Bernal 1



Section 1.	Identifying Inform	ation	
1. Given Name (Fi Yvette	rst Name)	2. Surname (Last Na Bernal	ame) 3. Date 16-March-2019
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Renier J. Brentjens
5. Manuscript Title Safety and tolera		hemotherapy follow	wed by CD19-targeted CAR T-cells for relapsed/refractory CLL
6. Manuscript lder 122627-INS-CME	ntifying Number (if you kr ED-RV-2	now it)	
Section 2.			
Did you or your ins any aspect of the s statistical analysis, Are there any rele	ubmitted work (including etc.)? evant conflicts of intere	ive payment or service but not limited to gra	es from a third party (government, commercial, private foundation, etc.) for ants, data monitoring board, study design, manuscript preparation,
	but the appropriate into be removed by pressin		ou have more than one entity press the "ADD" button to add a row.
Name of Institut	ion/Company	Grant? Persona	Non-Financial Support? Comments
luno Therapeutics			Financial support to institution (not to this individual) for the clinical trial described within the manuscript.
Section 3.	Relevant financial	activities outside	the submitted work.
of compensation clicking the "Add) with entities as descri +" box. You should rep	bed in the instruction to the court relationships the	ate whether you have financial relationships (regardless of amount ons. Use one line for each entity; add as many lines as you need by hat were present during the 36 months prior to publication .
Are there any rel	evant conflicts of intere	est?	No
Section 4.	Intellectual Proper	ty Patents & Co	ppyrights
Do you have any	patents, whether plan	ned, pending or issu	ued, broadly relevant to the work? ☐ Yes ✓ No

Bernal 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Bernal reports other from Juno Therapeutics, during the conduct of the study; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Bernal 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Sadelain 1



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Michel	2. Surname (Last Nar Sadelain	ne)	3. Date 16-March-2019
4. Are you the corresponding author?	☐ Yes ✓ No	uthor's Name jens	
5. Manuscript Title Safety and tolerability of conditioning	chemotherapy follow	ed by CD19-targeted C	AR T-cells for relapsed/refractory CLL
6. Manuscript Identifying Number (if you k 122627-INS-CMED-RV-2	now it)		
Section 2. The Work Under C	onsideration for P	ublication	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to gran		nment, commercial, private foundation, etc.) fo d, study design, manuscript preparation,
•			entity press the "ADD" button to add a row
Excess rows can be removed by pressir	ng the "X" button.		
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support?	Comments
Juno Therapeutics			Financial support to institution for the clinical trial described within the manuscript.
Section 3. Relevant financial	activities outside	the submitted work	•
	ribed in the instructior	ns. Use one line for eacl	ancial relationships (regardless of amount n entity; add as many lines as you need by the 36 months prior to publication.
Are there any relevant conflicts of inter		No	
If yes, please fill out the appropriate inf	ormation below.		
Name of Entity	Grant? Personal Fees?	Non-Financial Othe	Comments
Juno Therapeutics	V V		Consulting, advising, royalty sharing agreement, stock ownership, and research funding

Sadelain 2



Name of Entity	Grant?	Personal	Non-Financial	7	Comments
Name of Entity	Grant	Fees?	Support?	Other ?	Comments
Fate				✓	Collaborative research agreement
Atara				✓	Collaborative research agreement
Takeda				√	Collaborative research agreement; royalty
Berkeley Lights				✓	Scientific Advisory Board
Section 4. Intellectual Pro	operty Pate	ents & Cop	oyrights		
Do you have any patents, whether	planned, pend	ing or issue	ed, broadly releva		work? Yes No ty press the "ADD" button to add a row.
Patent? P	ending? Issue	ed ? Licens	ed? Royalties?	License	Comments
Nucleic acids encoding chimeric T cell receptors		<u> </u>		Juno Thera	Relevant to the 19-28z CAR T-cell design used in the report herein.
Section 5. Relationships	not covered	above			
Are there other relationships or act potentially influencing, what you v	tivities that read	ders could p		influence	d, or that give the appearance of
Yes, the following relationships No other relationships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/conditionships/					
At the time of manuscript acceptar On occasion, journals may ask auth	•				sary, update their disclosure statements. elationships.

Sadelain 3

Section 6. Disclosu

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Sadelain reports other from Juno Therapeutics, during the conduct of the study; grants, personal fees and other from Juno Therapeutics, other from Fate, other from Atara, other from Takeda, other from Berkeley Lights, outside the submitted work; In addition, Dr. Sadelain has a patent Nucleic acids encoding chimeric T cell receptors with royalties paid to Juno Therapeutics.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Sadelain 4



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



(5)				
Given Name (First Name) Jae	2. Surname (Last Name) Park			3. Date 16-March-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Correspond Renier J. Br	_	or's Name
5. Manuscript Title Safety and tolerability of conditioning	chemotherapy followed b	oy CD19-target	ted CAR	T-cells for relapsed/refractory CLL
6. Manuscript Identifying Number (if you k 122627-INS-CMED-RV-2	now it)			
Section 2. The Work Under C	Consideration for Publ	ication		
Did you or your institution at any time rece	eive payment or services fror	m a third narty (a	governme	ent commercial private foundation et
any aspect of the submitted work (includin statistical analysis, etc.)?	g but not limited to grants, d			
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter f yes, please fill out the appropriate inf	g but not limited to grants, drest? Yes No ormation below. If you ha	data monitoring	board, st	udy design, manuscript preparation,
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter If yes, please fill out the appropriate inf Excess rows can be removed by pressin	g but not limited to grants, of rest? Yes No rormation below. If you hang the "X" button. Grant? Personal No	data monitoring ave more than	board, st	udy design, manuscript preparation, ity press the "ADD" button to add a
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter f yes, please fill out the appropriate inf excess rows can be removed by pressing lame of Institution/Company	g but not limited to grants, of rest? Yes No rormation below. If you hang the "X" button. Grant? Personal No	ave more than	board, st one enti	udy design, manuscript preparation, ity press the "ADD" button to add a
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter of the statistical analysis, etc.)? Are there any relevant conflicts of interest of the state of the state of the state of the state of the submitted in the state of the state of the submitted in the state of the state of the submitted in the submitted in the state of the submitted in the sub	g but not limited to grants, of rest? Yes No rormation below. If you hang the "X" button. Grant? Personal No	ave more than	one enti	udy design, manuscript preparation, ity press the "ADD" button to add a Comments Financial support to institution for the clinical trial described within the
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intersection of the statistical analysis, etc.)? Are there any relevant conflicts of intersection of the statistical properties of the statistic of the submitted statistics of the submitted statistic of the submitted statistics of	g but not limited to grants, or rest? Yes No formation below. If you hang the "X" button. Grant? Personal No Fees?	ave more than	one enti	udy design, manuscript preparation, ity press the "ADD" button to add a Comments Financial support to institution for the clinical trial described within the
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter lifyes, please fill out the appropriate infexcess rows can be removed by pressir lifyes of Institution/Company The Therapeutics Itional Comprehensive Cancer Network ung Investigator Award Therican Society of Hematology The Geoffrey Beene Cancer Foundation	g but not limited to grants, or rest? Yes No Formation below. If you hang the "X" button. Grant? Personal Fees?	ave more than	one enti	udy design, manuscript preparation, ity press the "ADD" button to add a Comments Financial support to institution for the clinical trial described within the



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Amgen		✓		✓	Consulting/advisory role				
Juno Therapeutics		✓		✓	Consulting/advisory role; research funding				
Genentech/Roche				√	Research funding				
Novartis		✓		✓	Consulting				
GlaxoSmithKline		\checkmark		✓	Consulting				
Kite		\checkmark		✓	Consulting				
AstraZeneca		\checkmark		✓	Consulting				
Takeda		✓		✓	Consulting				
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No									
Section 5. Relationships not c	overed	above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?									
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	ow):				
✓ No other relationships/conditions/cir	✓ No other relationships/conditions/circumstances that present a potential conflict of interest								
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.									



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Park reports other from Juno Therapeutics, grants from National Comprehensive Cancer Network Young Investigator Award, grants from American Society of Hematology, grants from The Geoffrey Beene Cancer Foundation, grants from Leukemia and Lymphoma Society, during the conduct of the study; personal fees and other from Amgen, personal fees and other from Juno Therapeutics, other from Genentech/Roche, personal fees and other from Novartis, personal fees and other from GlaxoSmithKline, personal fees and other from Kite, personal fees and other from AstraZeneca, personal fees and other from Takeda, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation				
Given Name (First Name) Renier	2. Surnar Brentjen	ne (Last Nar Is	ne)		3. Date 16-March-2019
4. Are you the corresponding author?	✓ Yes	No			
5. Manuscript Title Safety and tolerability of conditioning ch	nemother	apy follow	ed by CD19-targe	eted CAR	T-cells for relapsed/refractory CLL
6. Manuscript Identifying Number (if you kno 122627-INS-CMED-RV-2	ow it)				
Section 2. The Work Under Co	nsidera	tion for P	ublication		
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interests	but not lim	nited to gran	its, data monitoring	board, st	udy design, manuscript preparation,
If yes, please fill out the appropriate info Excess rows can be removed by pressing			u have more than	one enti	ity press the "ADD" button to add a row.
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Damon Runyon Clinical Investigator Award	✓				
he Translational and Integrative Medicine Fund Research Grant	✓				
he Annual Terry Fox Run for Cancer Research New York, NY) organized by the Canada Club of New York	✓				
Carson Family Charitable Trust	\checkmark				
Cate's Team	\checkmark				
Ar. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research	✓				
he Experimental Therapeutics Center of MSKCC	✓				
he Geoffrey Beene Cancer Foundation	\checkmark				
he Bocina Cancer Research Fund	✓				
uno Therapeutics				✓	Financial support to institution for the clinical trial described within the



Name of Institution/Company	G	rant•	_	on-Financial Support	Other?	Comments			
Section 3. Polovent 6:0									
Place a check in the appropriate of compensation) with entities a clicking the "Add +" box. You sh Are there any relevant conflicts of the state of	boxes in the solution of the s	ne table to I in the ins relationsh	indicate what ructions. Unips that we	hether you ha Jse one line fo	ive financ or each en	ntity; add as many lines as you	ı need by		
Name of Entity	G	rant•	_	on-Financial Support	Other?	Comments			
Juno Therapeutics		✓	✓		✓	consulting, advising, royalty sha agreement, stock ownership, an research funding			
Celgene			✓		✓	consulting			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.									
Patent?	Pending?	Issued?	Licensed	Royalties?	License	e? Comments			
Nucleic acids encoding chimeric T cell receptors.		✓	✓	V	Juno Thera	Relevant to the 19-28z Cocell design used in the referein.			



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	ving relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. In als may ask authors to disclose further information about reported relationships.
Section 6.	
Section 6.	Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Brentjens reports grants from Damon Runyon Clinical Investigator Award, grants from The Translational and Integrative Medicine Fund Research Grant, grants from The Annual Terry Fox Run for Cancer Research (New York, NY) organized by the Canada Club of New York, grants from Carson Family Charitable Trust, grants from Kate's Team, grants from Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research, grants from The Experimental Therapeutics Center of MSKCC, grants from The Geoffrey Beene Cancer Foundation, grants from The Bocina Cancer Research Fund, other from Juno Therapeutics, from null, during the conduct of the study; grants, personal fees and other from Juno Therapeutics, other from Celgene, outside the submitted work; In addition, Dr. Brentjens has a patent Nucleic acids encoding chimeric T cell receptors. with royalties paid to Juno Therapeutics.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

TREND Statement Checklist

Paper	Item	Descriptor					
Section/ Topic	No						
Title and Abst	ract						
Title and	1	Information on how unit were allocated to interventions	√	2; 14-18			
Abstract		Structured abstract recommended	/	2			
		Information on target population or study sample	√	2; 3-4			
Introduction							
Background	2	Scientific background and explanation of rationale	/	3-4			
J		Theories used in designing behavioral interventions	N/A	N/A			
Methods	•		•	•			
Participants	3	Eligibility criteria for participants, including criteria at different levels in	√	15; Table S6			
		recruitment/sampling plan (e.g., cities, clinics, subjects)					
		Method of recruitment (e.g., referral, self-selection), including the	\checkmark	15			
		sampling method if a systematic sampling plan was implemented					
		Recruitment setting	√	15			
		Settings and locations where the data were collected	√	15			
Interventions	4	 Details of the interventions intended for each study condition and how and when they were actually administered, specifically including: 	\checkmark	15-17			
		Content: what was given?	./	15-17			
		Delivery method: how was the content given?	\/	15-16			
		 Unit of delivery: how were the subjects grouped during delivery? 	/	15-16			
		Deliverer: who delivered the intervention?	/	15-16			
		 Setting: where was the intervention delivered? 	/	15			
		 Exposure quantity and duration: how many sessions or episodes or events were intended to be delivered? How long were they intended to last? 	√	15-16			
		 Time span: how long was it intended to take to deliver the intervention to each unit? 	√	15-16			
		 Activities to increase compliance or adherence (e.g., incentives) 	N/A	N/A			
Objectives	5	Specific objectives and hypotheses	√	16			
Outcomes	6	Clearly defined primary and secondary outcome measures	\checkmark	16			
		Methods used to collect data and any methods used to enhance the quality of measurements	\checkmark	16-17			
		 Information on validated instruments such as psychometric and biometric properties 	√	16-17			
Sample Size	7	How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules	√	17			
Assignment Method	8	Unit of assignment (the unit being assigned to study condition, e.g., individual, group, community)	√	15-16			
		Method used to assign units to study conditions, including details of any restriction (e.g., blocking, stratification, minimization)	✓	15-16			
		Inclusion of aspects employed to help minimize potential bias induced due to non-randomization (e.g., matching)	N/A	N/A			

TREND Statement Checklist

Blinding	9	Whether or not participants, those administering the interventions, and	√	15
(masking)		those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed.	V	
Unit of Analysis	10	 Description of the smallest unit that is being analyzed to assess 	./	17
Offic of Attacysis	10	intervention effects (e.g., individual, group, or community)	V	
		If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)	N/A	N/A
Statistical Methods	11	Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data	✓	17-18
		Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis	✓	17-18
		Methods for imputing missing data, if used	√	17-18
		Statistical software or programs used	√	17-18
Results				
Participant flow	12	Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended)	√	4; Figure :
		 Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study 	✓	4; Figure
		 Assignment: the numbers of participants assigned to a study condition 	✓	4; Figure
		 Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention 	✓	4-8; Figur 1
		 Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition 	✓	4-10; Figure 1
		 Analysis: the number of participants included in or excluded from the main analysis, by study condition 	✓	4-10; Figure 1
		Description of protocol deviations from study as planned, along with reasons	N/A	N/A
Recruitment	13	Dates defining the periods of recruitment and follow-up	√	15
Baseline Data	14	Baseline demographic and clinical characteristics of participants in each study condition	✓	4-5; Table 1-2
		Baseline characteristics for each study condition relevant to specific disease prevention research	√	4-5; Table 1-2
		Baseline comparisons of those lost to follow-up and those retained, overall and by study condition	✓ <u> </u>	8; Tables 1-2
	1	Comparison between study population at baseline and target population	/	12
Baseline	15	of interest Data on study group equivalence at baseline and statistical methods used	N/A	N/A

TREND Statement Checklist

Numbers analyzed	16	 Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible 	√	4-10
		 Indication of whether the analysis strategy was "intention to treat" or, if not, description of how non-compliers were treated in the analyses 	✓	4-10; 13- 14
Outcomes and estimation	17	 For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision 	√	4-10; Figure 4
		Inclusion of null and negative findings	√	4-10
		 Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any 	N/A	N/A
Ancillary analyses	18	 Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory 	√	4-10 (w/ cited figs & tables)
Adverse events	19	 Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals) 	√	6-7; Table 4; Figures S3-4
DISCUSSION				
Interpretation	20	 Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study 	✓	10-14
		Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations	√	10-14
		 Discussion of the success of and barriers to implementing the intervention, fidelity of implementation 	/	10-14
		Discussion of research, programmatic, or policy implications	/	10-14
Generalizability	21	 Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues 	√	10-14
Overall Evidence	22	General interpretation of the results in the context of current evidence and current theory	✓	10-14

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: http://www.cdc.gov/trendstatement/